Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fimaporfin PCI plus gemcitabine/cisplatin versus gemcitabine/cisplatin in inoperable cholangiocarcinoma
2018-002647-29Phase 2Completed
- Sponsor
- PCI Biotech
- Start
- Nov 2018
- Modality
- Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in cholangiocarcinoma (CCA) comparing Fimaporfin PCI + gemcitabine/cisplatin with Gemcitabine/cisplatin (2 arms). Primary endpoint: Progression-free survival. Started Nov 2018; status: completed.
02
Drugs
fimaporfingemcitabinecisplatin
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on 2018-002647-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002647-29.